Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer

Inclusion Criteria

• •1. histologically- or cytologically-documented extensive-stage SCLC
• •2. to have received upfront treatment with Cisplatin/Carboplatin, etoposide and anti PD1/PD-L1 inhibitors
• •3. No evidence of brain metastases at diagnosis
• •4. ECOG PS 0-2
• •5. adult patients (aged ≥ 18 years) at diagnosis;
• •6. signing of informed consent approved by the local Ethic Committee